- All sections
- C - Chemistry; metallurgy
- C07K - Peptides
- C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Patent holdings for IPC class C07K 16/00
Total number of patents in this class: 11355
10-year publication summary
833
|
902
|
873
|
811
|
872
|
811
|
736
|
664
|
509
|
137
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Regeneron Pharmaceuticals, Inc. | 3650 |
246 |
Amgen Inc. | 3779 |
242 |
Genentech, Inc. | 3742 |
216 |
F. Hoffmann-La Roche AG | 7958 |
163 |
Chugai Seiyaku Kabushiki Kaisha | 1259 |
145 |
The Regents of the University of California | 18943 |
138 |
Hoffmann-La Roche Inc. | 3060 |
134 |
Xencor, Inc. | 403 |
108 |
Novartis AG | 11238 |
99 |
Abbvie Inc. | 1808 |
93 |
Pfizer Inc. | 3322 |
71 |
Bristol-myers Squibb Company | 5080 |
66 |
Janssen Biotech, Inc. | 1347 |
63 |
Cytiva BioProcess R&D AB | 287 |
61 |
Zymeworks Inc. | 234 |
60 |
Ablynx N.V. | 377 |
58 |
Sanofi | 3836 |
57 |
MedImmune, LLC | 467 |
56 |
SeaGen Inc | 554 |
56 |
Merck Patent GmbH | 5909 |
54 |
Other owners | 9169 |